U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Al.3F
Molecular Weight 83.9767482
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALUMINUM FLUORIDE

SMILES

[F-].[F-].[F-].[Al+3]

InChI

InChIKey=KLZUFWVZNOTSEM-UHFFFAOYSA-K
InChI=1S/Al.3FH/h;3*1H/q+3;;;/p-3

HIDE SMILES / InChI

Molecular Formula FH
Molecular Weight 20.00634
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Al
Molecular Weight 26.9815386
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/algeldrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18362170 | https://www.ncbi.nlm.nih.gov/pubmed/12222737 | https://www.ncbi.nlm.nih.gov/pubmed/9115023 | https://www.ncbi.nlm.nih.gov/pubmed/15479434

Algeldrate (Aluminium hydroxide) is the amphoteric inorganic compound used as an antacid in the treatment of Duodenal, Peptic and Stomach Ulcer and some other conditions. Aluminium hydroxide is preferred over other alternatives such as sodium bicarbonate because Al(OH)3, being insoluble, does not increase the pH of stomach above 7 and hence, does not trigger secretion of excess acid by the stomach. Brand names include Alu-Cap, Aludrox, Gaviscon or Pepsamar. It reacts with the excess acid in the stomach, reducing the acidity of the stomach content, which may relieve the symptoms of ulcers, heartburn or dyspepsia. Such products can cause constipation, because the aluminum ions inhibit the contractions of smooth muscle cells in the gastrointestinal tract, slowing peristalsis and lengthening the time needed for stool to pass through the colon. Some such products (such as Maalox) are formulated to minimize such effects through the inclusion of equal concentrations of magnesium hydroxide or magnesium carbonate, which have counterbalancing laxative effects. This compound is also used to control phosphate (phosphorus) levels in the blood of people suffering from kidney failure. Precipitated aluminum hydroxide is included as an adjuvant in some vaccines (e.g. anthrax vaccine). One of the well-known brands of aluminum hydroxide adjuvant is Alhydrogel, made by Brenntag Biosector. Since it absorbs protein well, it also functions to stabilize vaccines by preventing the proteins in the vaccine from precipitating or sticking to the walls of the container during storage. Aluminium hydroxide is sometimes mistakenly called "alum", which properly refers to aluminum potassium sulfate. Vaccine formulations containing aluminum hydroxide stimulate the immune system by inducing the release of uric acid, an immunological danger signal. This strongly attracts certain types of monocytes which differentiate into dendritic cells. The dendritic cells pick up the antigen, carry it to lymph nodes, and stimulate T cells and B cells. It appears to contribute to induction of a good Th2 response, so is useful for immunizing against pathogens that are blocked by antibodies. In the 1960s and 1970s, it was speculated that aluminum was related to various neurological disorders including Alzheimer's disease. Since then, multiple epidemiological studies have found no connection between exposure to aluminum and neurological disorders.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Alhydrogel

Approved Use

Unknown
Primary
Gelusil-Lac

Approved Use

Unknown
Primary
Gastracid

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Toxicoproteomic analysis of pulmonary carbon nanotube exposure using LC-MS/MS.
2015-03-02
Pesticide exposure and depression among male private pesticide applicators in the agricultural health study.
2014-09
Atomic layer deposition coating of carbon nanotubes with aluminum oxide alters pro-fibrogenic cytokine expression by human mononuclear phagocytes in vitro and reduces lung fibrosis in mice in vivo.
2014
New insight into artifactual phenomena during in vitro toxicity assessment of engineered nanoparticles: study of TNF-α adsorption on alumina oxide nanoparticle.
2013-04
Effect of acute aluminum phosphide exposure on rats: a biochemical and histological correlation.
2012-11-23
Al₂O₃ nanoparticles induce mitochondria-mediated cell death and upregulate the expression of signaling genes in human mesenchymal stem cells.
2012-11
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012-04
Blood levels of methemoglobin in patients with aluminum phosphide poisoning and its correlation with patient's outcome.
2011-03
In vivo toxicity of nano-alumina on mice neurobehavioral profiles and the potential mechanisms.
2011-02-19
Aluminum nanoparticle exposure in L1 larvae results in more severe lethality toxicity than in L4 larvae or young adults by strengthening the formation of stress response and intestinal lipofuscin accumulation in nematodes.
2011-01
Altered glucose homeostasis in response to aluminium phosphide induced cellular oxygen deficit in rat.
2010-07
Inhibition of a protein tyrosine phosphatase using mesoporous oxides.
2010-03-11
The effects of implant surface nanoscale features on osteoblast-specific gene expression.
2009-09
Aluminum phosphide fatalities at mild exertion in asymptomatic children: a clue to understand the variations of the autopsy findings.
2009-08
Retrospective analysis of 4-week inhalation studies in rats with focus on fate and pulmonary toxicity of two nanosized aluminum oxyhydroxides (boehmite) and pigment-grade iron oxide (magnetite): the key metric of dose is particle mass and not particle surface area.
2009-05-17
Efficacy of simple short-term in vitro assays for predicting the potential of metal oxide nanoparticles to cause pulmonary inflammation.
2009-02
Hyperglycemia in acute aluminum phosphide poisoning as a potential prognostic factor.
2008-07
Alumina nanoparticles induce expression of endothelial cell adhesion molecules.
2008-05-30
Human macrophage response to UHMWPE, TiAlV, CoCr, and alumina particles: analysis of multiple cytokines using protein arrays.
2008-02
Reversible myocardial injury associated with aluminum phosphide poisoning.
2007-09
Microdermabrasion with and without aluminum oxide crystal abrasion: a comparative molecular analysis of dermal remodeling.
2006-03
An effector domain mutant of Arf6 implicates phospholipase D in endosomal membrane recycling.
2006-01
Large aqueous aluminum hydroxide molecules.
2006-01
Cytochrome-c oxidase inhibition in 26 aluminum phosphide poisoned patients.
2006
Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles.
2005-05
The influence of alumina and ultra-high molecular weight polyethylene particles on osteoblast-osteoclast cooperation.
2004-08
Comparison of the response of primary human blood monocytes and the U937 human monocytic cell line to two different sizes of alumina ceramic particles.
2004-07
The giant protein HERC1 is recruited to aluminum fluoride-induced actin-rich surface protrusions in HeLa cells.
2004-02-13
Matrix metalloproteinases MMP-2, -9 and tissue inhibitors TIMP-1, -2 expression and secretion by primary human osteoblast cells in response to titanium, zirconia, and alumina ceramics.
2004-01-01
Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants.
2002-11
Bone cell mitogenic action of fluoroaluminate and aluminum fluoride but not that of sodium fluoride involves upregulation of the insulin-like growth factor system.
2002-05
Effects of polyethylene and alpha-alumina particles on IL-6 expression and secretion in primary cultures of human osteoblastic cells.
2002-02
Quartz exposure of the rat lung leads to a linear dose response in inflammation but not in oxidative DNA damage and mutagenicity.
2001-04
Effect of N-acetylcysteine and L-NAME on aluminium phosphide induced cardiovascular toxicity in rats.
2001-04
Cholinesterase inhibition by aluminium phosphide poisoning in rats and effects of atropine and pralidoxime chloride.
2001-01
Intravascular hemolysis in aluminium phosphide poisoning.
1999-09
[TNF-alpha secretion by human macrophage-like cells in response to wear particles and its modification by drugs].
1999-05
Effect of aluminum phosphide on blood glucose level.
1999-02
Manipulation of B cell antigen receptor tyrosine phosphorylation using aluminum fluoride and sodium orthovanadate.
1995-11
Requirement for intramolecular domain interaction in activation of G protein alpha subunit by aluminum fluoride and GDP but not by GTP gamma S.
1994-11-25
Hypermagnesemia following aluminum phosphide poisoning.
1991-02
Plasma renin activity in shock due to aluminium phosphide poisoning.
1990-06
Aluminum fluoride inhibition of glucocorticoid receptor inactivation and transformation.
1990-04-10
Cardiovascular manifestations of aluminium phosphide intoxication.
1989-09
Aluminum fluoride induces phosphatidylinositol turnover, elevation of cytoplasmic free calcium, and phosphorylation of the T cell antigen receptor in murine T cells.
1987-11-15
Patents

Sample Use Guides

Adults and children over 15 years: 1-2 table (400-800ьп). 4 times a day 1 hour after meals and in the evening before bed or if there is discomfort, epigastric pain, heartburn.
Route of Administration: Oral
Bone marrow cells were cultured for 9 d in dendritic cells (DC) culture medium (DC-CM; RPMI 1640 containing GlutaMAX-I; Invitrogen) supplemented with 5% (vol/vol) FCS (Sigma-Aldrich), 50 μ M 2-mercaptoethanol (Sigma-Aldrich), 50 μ g/ml gentamicin (Invitrogen), and 20 ng/ml recombinant mouse GM-CSF (a gift from K. Thielemans, Vrije Universiteit Brussel, Brussels, Belgium). 16 h before harvesting, DCs were exposed either to 10 μ g/ml of OVA, alum (Algeldrate), or OVA-alum suspension.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:25:56 GMT 2025
Edited
by admin
on Mon Mar 31 19:25:56 GMT 2025
Record UNII
Z77H3IKW94
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALUMINUM FLUORIDE [HSDB]
Preferred Name English
ALUMINUM FLUORIDE
HSDB   INCI   MI  
INCI  
Official Name English
ALUMINUM FLUORIDE [MI]
Common Name English
ALUMINUM TRIFLUORIDE
Systematic Name English
Code System Code Type Description
WIKIPEDIA
Aluminum fluoride
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
PUBCHEM
2124
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
CHEBI
49464
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
FDA UNII
Z77H3IKW94
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
DAILYMED
Z77H3IKW94
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
EPA CompTox
DTXSID8030712
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
HSDB
600
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
CAS
7784-18-1
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
ECHA (EC/EINECS)
232-051-1
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
MESH
C032311
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
MERCK INDEX
m1605
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY Merck Index
RXCUI
2273602
Created by admin on Mon Mar 31 19:25:56 GMT 2025 , Edited by admin on Mon Mar 31 19:25:56 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE